Sarepta Therapeutics experienced a notable market move after publishing initial clinical readouts from its siRNA development program targeting facioscapulohumeral muscular dystrophy type 1 (FSHD1) and myotonic dystrophy type 1 (DM1). Shares rose 14% following the release of early data from first-in-human, Phase 1/2 ascending dose studies of SRP-1001 (FSHD1) and SRP-1003 (DM1).
The Cambridge, Massachusetts-based company said the trials demonstrated dose-dependent muscle exposure and early biomarker effects, alongside a tolerability profile it characterized as favorable. Sarepta reported proof-of-concept findings indicating that a single administered dose of both SRP-1001 and SRP-1003 supported reductions in the targeted protein or mRNA.
Investigators recorded adverse events in study participants, but the company emphasized that the majority were mild to moderate and did not appear to vary with dose. Sarepta described no dose-limiting safety signals to date in these early cohorts.
Both investigational therapies rely on an alpha-v beta-6 integrin-targeted delivery platform engineered to transport siRNA into cells and enable penetration into muscle tissue. According to the company, this delivery approach is intended to confront the delivery and safety challenges that have affected other RNA-targeted strategies for rare genetic diseases driven by overexpression of mutant proteins or toxic mRNA.
Louise Rodino-Klapac, President of Research & Development and Technical Operations, said the early clinical results showed high levels of siRNA delivery to muscle, with no saturation of muscle siRNA uptake or dose-limiting safety signals to date.
Sarepta indicated it will host an investor call on March 25, 2026 at 8:30 a.m. Eastern time to discuss the data.
The company’s announcement links translational pharmacology observations - muscle exposure and biomarker responses - with an early clinical safety readout. Because these are ascending dose Phase 1/2 studies, the results are initial and focused on demonstrating delivery, biological effect, and short-term tolerability rather than long-term efficacy.
Market context
The stock reaction reflects investor interest in early clinical evidence that an siRNA delivery strategy can reach muscle tissue and produce measurable biological changes after a single dose. Market participants often weigh such early proof-of-concept data against the remaining development milestones that will be necessary to establish therapeutic benefit and long-term safety.